Research ArticleOriginal Article
Open Access

Serostatus of IgG antibody against mumps virus in adult population of Al Madinah Al Munawarah, Saudi Arabia

Waleed H. Mahallawi, Mohiadeen M. Kurdi and Nadir A. Ibrahim
Saudi Medical Journal August 2021, 42 (8) 862-868; DOI: https://doi.org/10.15537/smj.2021.42.8.20210228

References

  1. 1.↵
    1. Mclean HQ,
    2. Hickman C,
    3. Seward JF.
    Organization WH, Control CfD, Prevention. The immunological basis for immunization series: module 16: mumps. 2010.
  2. 2.↵
    1. Davison P,
    2. Morris J. Mumps
    . StatPearls [Internet]: StatPearls Publishing; 2019.
  3. 3.↵
    1. Ma R,
    2. Lu L,
    3. Zhou T,
    4. Pan J,
    5. Chen M,
    6. Pang X.
    Mumps disease in Beijing in the era of two-dose vaccination policy, 2005-2016. Vaccine 2018; 36: 2589–2595.
    OpenUrl
  4. 4.↵
    1. Masarani M,
    2. Wazait H,
    3. Dinneen M.
    Mumps orchitis. J R Soc Med 2006; 99: 573–575.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Lane TM,
    2. Hines J.
    The management of mumps orchitis. BJU Int 2006; 97: 1–2.
    OpenUrlPubMed
  6. 6.
    1. Philip J,
    2. Selvan D,
    3. Desmond AD.
    Mumps orchitis in the non-immune postpubertal male: a resurgent threat to male fertility? BJU Int 2006; 97: 138–141.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Choi HI,
    2. Yang DM,
    3. Kim HC,
    4. Kim SW,
    5. Jeong HS,
    6. Moon SK, et al.
    Testicular atrophy after mumps orchitis: ultrasonographic findings. Ultrasonography 2020; 39: 266–271.
    OpenUrl
  8. 8.↵
    1. Coppeta L,
    2. Balbi O,
    3. Baldi S,
    4. Pietroiusti A,
    5. Magrini A.
    Pre-vaccination IgG screening for mumps is the most cost-effectiveness immunization strategy among Health Care Workers. Hum Vaccin Immunother 2019; 15: 1135–1138.
    OpenUrl
  9. 9.↵
    Organization WH. Weekly Epidemiological Record, 2007, vol. 82, 21 [full issue]. Weekly Epidemiological Record= Relevé épidémiologique hebdomadaire. 2007;82(7):49–60.
  10. 10.↵
    1. Amanna IJ,
    2. Carlson NE,
    3. Slifka MK.
    Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007; 357: 1903–1915.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Kontio M,
    2. Jokinen S,
    3. Paunio M,
    4. Peltola H,
    5. Davidkin I.
    Waning antibody levels and avidity: implications for MMR vaccine-induced protection. J Infect Dis 2012; 206: 1542–1548.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Connell AR,
    2. Connell J,
    3. Leahy TR,
    4. Hassan J.
    Mumps outbreaks in vaccinated populations-is it time to re-assess the clinical efficacy of vaccines? Front Immunol 2020; 11: 2089.
    OpenUrl
  13. 13.↵
    1. Fields VS,
    2. Safi H,
    3. Waters C,
    4. Dillaha J,
    5. Capelle L,
    6. Riklon S, et al.
    Mumps in a highly vaccinated Marshallese community in Arkansas, USA: an outbreak report. The Lancet Infectious Diseases 2019; 19: 185–192.
    OpenUrlCrossRef
  14. 14.
    1. Memish ZA,
    2. Al-Tawfiq JA,
    3. Assiri A,
    4. Mohammed M,
    5. Bamgboye EA,
    6. Alhakeem R.
    Epidemiology of mumps and rubella in the Kingdom of Saudi Arabia: 2009-2011-Implications for immigration and travel. Travel Med Infect Dis 2015; 3: 261–262.
    OpenUrl
  15. 15.
    1. Patel C,
    2. Beard F,
    3. Hendry A,
    4. Quinn H,
    5. Dey A,
    6. Macartney K, et al.
    Australian mumps serosurvey 2012-2013: any cause for concern? Commun Dis Intell (2018) 2020; 44. doi: 10.33321/cdi.2020.44.67.
  16. 16.
    1. Rasheed MAU,
    2. Hickman CJ,
    3. McGrew M,
    4. Sowers SB,
    5. Mercader S,
    6. Hopkins A, et al.
    Decreased humoral immunity to mumps in young adults immunized with MMR vaccine in childhood. Proc Natl Acad Sci U S A 2019; 116: 19071–19076.
    OpenUrlAbstract/FREE Full Text
  17. 17.
    1. Smits G,
    2. Mollema L,
    3. Hahné S,
    4. de Melker H,
    5. Tcherniaeva I,
    6. Waaijenborg S, et al.
    Seroprevalence of mumps in The Netherlands: dynamics over a decade with high vaccination coverage and recent outbreaks. PLoS One 2013; 8: e58234.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. González-Escalada A,
    2. García-García L,
    3. Viguera-Ester P,
    4. Marín-García P,
    5. García J,
    6. Gil-de-Miguel A, et al.
    Seroprevalence of antibodies against measles, rubella, mumps, varicella-zoster, and B. Pertussis in young adults of Madrid, Spain. Hum Vaccin Immunother 2013; 9: 1918–1925.
    OpenUrlCrossRefPubMed
  19. 19.
    1. Pang H,
    2. Zhou Y,
    3. Zhao W,
    4. Jiang Q.
    Seroprevalence and determinants associated with mumps antibodies after 20 years of MMR vaccination in urban area of Shanghai, China. Int J Environ Res Public Health 2018; 15: 2089.
    OpenUrl
  20. 20.↵
    1. Santacruz-Sanmartín E,
    2. Hincapié-Palacio D,
    3. Ospina MC,
    4. Perez-Toro O,
    5. Bernal-Restrepo LM,
    6. Buitrago-Giraldo S, et al.
    Seroprevalence of mumps in an epidemic period in Medellín, Colombia. Vaccine 2015; 33: 5606–5612.
    OpenUrl
  21. 21.↵
    1. Lewnard JA,
    2. Grad YH.
    Vaccine waning and mumps re-emergence in the United States. Sci Transl Med 2018; 10: eaao5945.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Almansour I.
    Mumps Vaccines: Current Challenges and Future Prospects. Front Microbiol 2020;11; 1999.
  23. 23.↵
    1. Alsibiani SA.
    Rubella immunity among pregnant women in Jeddah, Western region of Saudi Arabia. Obstet Gynecol Int 2014; 2014: 659838.
    OpenUrl
  24. 24.
    Ministry of Health. Basic Vaccination Schedule [Internet]. Saudi Ministry of Health. [Updated 2018; accessed 2021 Mar 18]. Available from: https://www.moh.gov.sa/en/HealthAwareness/EducationalContent/HealthTips/Documents/Immunization-Schedule.pdf.
  25. 25.↵
    1. Tufenkeji H,
    2. Kattan H.
    Childhood immunization in the Kingdom of Saudi Arabia. Ann Saudi Med 1994; 14: 91–93.
    OpenUrlPubMed
  26. 26.↵
    1. Damm O,
    2. Witte J,
    3. Wetzka S,
    4. Prosser C,
    5. Braun S,
    6. Welte R, et al.
    Epidemiology and economic burden of measles, mumps, pertussis, and varicella in Germany: a systematic review. Int J Public Health 2016; 61: 847–860.
    OpenUrl
  27. 27.↵
    1. Su SB,
    2. Chang HL,
    3. Chen KT.
    Current status of mumps virus infection: epidemiology, pathogenesis, and vaccine. Int J Environ Res Public Health 2020; 17: 1686.
    OpenUrl
  28. 28.↵
    1. Rubin S,
    2. Eckhaus M,
    3. Rennick LJ,
    4. Bamford CG,
    5. Duprex WP.
    Molecular biology, pathogenesis and pathology of mumps virus. J Pathol 2015; 235: 242–252.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Barskey AE,
    2. Glasser JW,
    3. LeBaron CW.
    Mumps resurgences in the United States: A historical perspective on unexpected elements. Vaccine 2009; 27: 6186–6195.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    1. Rasheed MAU,
    2. Hickman CJ,
    3. McGrew M,
    4. Sowers SB,
    5. Mercader S,
    6. Hopkins A, et al.
    Decreased humoral immunity to mumps in young adults immunized with MMR vaccine in childhood. Proc Natl Acad Sci U S A 2019; 116: 19071–19076.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Kim SK,
    2. Jung J,
    3. Kwak SH,
    4. Hong MJ,
    5. Kim SH.
    Seroprevalence of mumps in healthcare workers in South Korea. Clin Exp Vaccine Res 2020; 9: 64–67.
    OpenUrl
  32. 32.↵
    1. Plans P.
    New preventive strategy to eliminate measles, mumps and rubella from Europe based on the serological assessment of herd immunity levels in the population. Eur J Clin Microbiol Infect Dis 2013; 32: 961–966.
    OpenUrlCrossRefPubMed
  33. 33.↵
    World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2020 global summary. [Updated 2020 July 15; accessed 2021 Mar 18]. Available from: https://apps.who.int/immunization_monitoring/globalsummary/incidences?c=SAU.
  34. 34.↵
    Saudi Press Agency. National immunization campaign against measles, rubella, mumps starts in Saudi Arabia. [Updated 2011 September 17; accessed 2021 Mar 15]. Available from: https://www.spa.gov.sa/925541.
  35. 35.↵
    Arab News. MMR vaccination campaign launched. [Updated 2013 November 18, accessed 2021 Mar 15]. Available from: https://www.arabnews.com/news/479256.
  36. 36.↵
    1. Davidkin I,
    2. Kontio M,
    3. Paunio M,
    4. Peltola H.
    MMR vaccination and disease elimination: the Finnish experience. Expert Rev Vaccines 2010; 9: 1045–1053.
    OpenUrlCrossRefPubMedWeb of Science
  37. 37.↵
    1. Poethko-Müller C,
    2. Mankertz A.
    Seroprevalence of measles-, mumps-and rubella-specific IgG antibodies in German children and adolescents and predictors for seronegativity. PLoS One 2012; 7: e42867.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Madi N,
    2. Altawalah H,
    3. Alfouzan W,
    4. Al-Nakib W,
    5. Al-Roumi E,
    6. Jeragh A.
    Assessment of immune status against measles, mumps, and rubella in young Kuwaitis: MMR vaccine efficacy. J Med Virol 2020; 92: 963–970.
    OpenUrl
  39. 39.↵
    1. Eriksen J,
    2. Davidkin I,
    3. Kafatos G,
    4. Andrews N,
    5. Barbara C,
    6. Cohen D, et al.
    Seroepidemiology of mumps in Europe (1996-2008): why do outbreaks occur in highly vaccinated populations? Epidemiol Infect 2013; 141: 651–666.
    OpenUrlCrossRefWeb of Science
  40. 40.↵
    1. Tischer A,
    2. Andrews N,
    3. Kafatos G,
    4. Nardone A,
    5. Berbers G,
    6. Davidkin I, et al.
    Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia. Epidemiol Infect 2007; 135: 787–797.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    1. Harling R,
    2. White JM,
    3. Ramsay ME,
    4. Macsween KF,
    5. van den Bosch C.
    The effectiveness of the mumps component of the MMR vaccine: a case control study. Vaccine 2005; 23: 4070–4074.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    1. Schaffzin JK,
    2. Pollock L,
    3. Schulte C,
    4. Henry K,
    5. Dayan G,
    6. Blog D, et al.
    Effectiveness of previous mumps vaccination during a summer camp outbreak. Pediatrics 2007; 120: e862–e868.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Rosario-Rosario G,
    2. Gareca M,
    3. Kincaid H,
    4. Knouse MC.
    Using locally derived seroprevalence data on measles, mumps, rubella, and varicella by birth cohort to determine risks for vaccine-preventable diseases during international travel. J Travel Med 2015; 22: 396–402.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Kenny L,
    2. O’Kelly E,
    3. Connell J,
    4. De Gascun C,
    5. Hassan J.
    Mumps outbreaks in a highly vaccinated population: Investigation of a neutralization titre against the current circulating wildtype genotype G5 mumps virus. Journal of clinical virology. J Clin Virol 2016; 74: 8–12.
    OpenUrl
  45. 45.↵
    1. Mahallawi WH,
    2. Ibrahim NA.
    Seroprevalence against the measles virus after vaccination or natural infection in an adult population in Madinah, Saudi Arabia. Hum Vaccin Immunother 2021; 11: 1–8.
    OpenUrl
  46. 46.↵
    1. Matter L,
    2. Germann D,
    3. Bally F,
    4. Schopfer K.
    Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination. Eur J Epidemiol 1997; 13: 61–66.
    OpenUrlCrossRefPubMed
  47. 47.↵
    1. Carr MJ,
    2. Moss E,
    3. Waters A,
    4. Dean J,
    5. Jin L,
    6. Coughlan S, et al.
    Molecular Epidemiological Evaluation of the Recent Resurgence in Mumps Virus Infections in Ireland. J Clin Microbiol 2010; 48: 3288–3294.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords